Understanding the mechanisms of aromatase inhibitor resistance

Breast Cancer Research

Volumn 14, Issue 1, 2012, Pages

  Miller, William R ^a   Larionov, Alexey A ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE; AROMATASE INHIBITOR; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; COLLAGEN; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; FULVESTRANT; GEFITINIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEOGLYCAN; TAMOXIFEN; TRASTUZUMAB; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); CROSS RESISTANCE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; ENZYME INHIBITION; ESTRADIOL BLOOD LEVEL; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; MONOTHERAPY; NONHUMAN; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; BREAST NEOPLASMS; DRUG RESISTANCE; ENZYMOLOGY; FEMALE; METABOLISM;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTROGENS; FEMALE; HUMANS;

EID: 84856149493     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2931     Document Type: Review

References (78)

1. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005, 23:619-629.
2. Miller WR. Aromatase inhibitors and breast cancer. Minerva Endocrinol 2006, 31:27-46.
3. Lonning PE. Pharmacology of new aromatase inhibitors. Breast 1996, 5:202-206.
4. Geisler J, Haynes B, Anker G, Dowsett M, Lønning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002, 20:751-757. 10.1200/JCO.20.3.751, 11821457.
5. Dowsett M. Preoperative models to evaluate endocrine strategies for breast cancer. Clin Cancer Res 2003, 9:502S-510S.
6. Anderson TJ, Dixon JM, Stuart M, Sahmoud T, Miller WR. Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer. Br J Cancer 2002, 87:334-338. 10.1038/sj.bjc.6600435, 2364231, 12177804.
7. Dixon JM. Neoadjuvant therapy: surgical perspectives. Endocrine Therapy in Breast Cancer 2002, 197-212. New York: Marcel Dekker, Miller WR, Ingle JN.
8. Miller WR, Jackson J. The therapeutic potential of aromatase inhibitors. Expert Opin Investig Drugs 2003, 12:1-12. 10.1517/13543784.12.1.1, 12517249.
9. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, Dugan M, Borgs M, Letrozole Neo-Adjuvant Breast Cancer Study Group Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001, 12:1527-1532. 10.1023/A:1013128213451, 11822750, Letrozole Neo-Adjuvant Breast Cancer Study Group.
10. Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G, IMPACT Trialists Group Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005, 23:5108-5116. 10.1200/JCO.2005.04.005, 15998903, IMPACT Trialists Group.
11. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyld P, Bhatnagar A. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003, 21:2101-2109. 10.1200/JCO.2003.04.194, 12775735.
12. Johnston SR, Martin LA, Head J, Smith I, Dowsett M. Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance. J Steroid Biochem Mol Biol 2005, 95:173-181. 10.1016/j.jsbmb.2005.04.004, 15996863.
13. Miller WR, Larionov A. Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole. Breast Cancer Res 2010, 12:R52. 10.1186/bcr2611, 2949641, 20646288.
14. Miller WR, White S, Dixon JM, Murray J, Renshaw L, Anderson TJ. Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. Br J Cancer 2006, 94:1051-1056. 10.1038/sj.bjc.6603001, 2361236, 16538221.
15. Miller WR, Larionov AA, Renshaw L, Anderson TJ, White S, Murray J, Murray E, Hampton G, Walker JR, Ho S, Krause A, Evans DB, Dixon JM. Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenet Genomics 2007, 17:813-826. 10.1097/FPC.0b013e32820b853a, 17885619.
16. Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K, Ashworth A, Drury S, Larionov A, Young O, White S, Miller WR, Evans DB, Dowsett M. Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res 2007, 9:R37. 10.1186/bcr1732, 1929101, 17555561.
17. Geisler J, Lonning PE. Resistance to endocrine therapy of breast cancer: recent advances and tomorrow's challenges. Clin Breast Cancer 2001, 1:297-308. 10.3816/CBC.2001.n.004, 11899352.
18. Perey L, Paridaens R, Hawle H, Zaman K, Nolé F, Wildiers H, Fiche M, Dietrich D, Clément P, Köberle D, Goldhirsch A, Thürlimann B. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol 2007, 18:64-69.
19. Johnston S. Fulvestrant and the sequential endocrine cascade for advanced breast cancer. Br J Cancer 2004, 90(Suppl 1):S15-18. 2750772, 15094760.
20. Lonning PE. Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?. Eur J Cancer 2009, 45:527-535. 10.1016/j.ejca.2008.10.019, 19062270.
21. Beresford M, Tumur I, Chakrabarti J, Barden J, Rao N, Makris A. A qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancer. Clin Oncol (R Coll Radiol) 2011, 23:209-215. 10.1016/j.clon.2010.11.005, 21134732.
22. Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, Piccart MJ, Bogaerts J, Therasse P. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the european organisation for research and treatment of cancer breast cancer cooperative group. Ann Oncol 2003, 14:1391-1398. 10.1093/annonc/mdg362, 12954578.
23. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001, 19:3808-3816.
24. Ingle JN, Johnson PA, Suman VJ, Gerstner JB, Mailliard JA, Camoriano JK, Gesme DH, Loprinzi CL, Hatfi eld AK, Hartmann LC. A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. Cancer 1997, 80:218-224. 10.1002/(SICI)1097-0142(19970715)80:2<218::AID-CNCR8>3.0.CO;2-P, 9217033.
25. Jones S, Vogel C, Arkhipov A, Fehrenbacher L, Eisenberg P, Cooper B, Honig S, Polli A, Whaley F, di Salle E, Tiffany J, Consonni A, Miller L. Multicenter, Phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. J Clin Oncol 1999, 17:3418-3425.
26. Rose C. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer. Am J Clin Oncol 2003, 26(suppl 1):S9-S16.
27. Paepke S, Tulusan A, Kiesel L, Bastert G, Jaenicke FK, Bouterfa H, Wackwitz B. A multi-center study of pre-operative treatment with letrozole for optimal duration of treatment in postmenopausal women with ER and/or PgR positive breast cancer. Proc Am Soc Clin Oncol 2003, Abstract 321.
28. Dixon JM, Renshaw L, Macaskill EJ, Young O, Murray J, Cameron D, Kerr GR, Evans DB, Miller WR. Increase in response rate by prolonged treatment with neoadjuvant letrozole. Breast Cancer Res Treat 2009, 113:145-151. 10.1007/s10549-008-9915-6, 18264759.
29. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Hope S. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009, 27:2630-2637. 10.1200/JCO.2008.18.8391, 19380449.
30. Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena FP, Kroener JF, Curcio E, Watkins C, Bacus S, Cora EM, Anderson E, Magill PJ. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res 2010, 16:1904-1914. 10.1158/1078-0432.CCR-09-2282, 20215537.
31. Smith IE, Walsh G, Skene A, Llombart A, Mayordom JI, Detre S, Salter J, Clark E, Magill P, Dowsett M. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol 2007, 25:3816-3822. 10.1200/JCO.2006.09.6578, 17679728.
32. Johnston S, Pippen J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikha A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009, 27:5538-5546. 10.1200/JCO.2009.23.3734, 19786658.
33. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, Révil C, Jones A. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized Phase III TAnDEM Study. J Clin Oncol 2009, 27:5529-5537. 10.1200/JCO.2008.20.6847, 19786670.
34. Murray R, Pitt P. Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res Treat 1995, 35:249-253. 10.1007/BF00665976, 7579495.
35. Geisler J, Johannessen DC, Anker G, Lønning PE. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: Clinical and endocrine effects. Eur J Cancer 1996, 32A:789-792. 10.1016/0959-8049(95)00623-0, 9081355.
36. Lønning PE, Bajetta E, Murray R, Tubiana-Hulin M, Eisenberg PD, Mickiewicz E, Celio L, Pitt P, Mita M, Aaronson NK, Fowst C, Arkhipov A, di Salle E, Polli A, Massimini G. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000, 18:2234-2244.
37. Bertelli G, Garrone O, Merlano M, Occelli M, Bertolotti L, Castiglione F, Pepi F, Fusco O, Del Mastro L, Leonard RC. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 2005, 69:471-477. 10.1159/000090985, 16410685.
38. Miller WR, Bartlett J, Brodie AM, Brueggemeier RW, di Salle E, Lønning PE, Llombart A, Maass N, Maudelonde T, Sasano H, Goss PE. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?. Oncologist 2008, 13:829-837. 10.1634/theoncologist.2008-0055, 18695261.
39. Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008, 26:1664-1670. 10.1200/JCO.2007.13.5822, 18316794.
40. Bunone G, Briand PA, Miksicek RJ, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996, 15:2174-2183. 450141, 8641283.
41. Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 2006, 24:3019-3025. 10.1200/JCO.2005.04.3034, 16754938.
42. Dixon JM, Jackson J, Hills M, Renshaw L, Cameron DA, Anderson TJ, Miller WR, Dowsett M. Anastrozole demonstrates clinical and biological effectiveness in oestrogen reception-positive breast cancers, irrespective of the erbB2 status. Eur J Cancer 2004, 40:2742-2747. 10.1016/j.ejca.2004.08.025, 15571956.
43. Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon M, Ebbs S, Gui G, Sacks N, Smith I. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 2001, 61:8452-8458.
44. Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G, BIG 1-98 Collaborative and International Breast Cancer Study Groups Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 2008, 9:23-28. 10.1016/S1470-2045(07)70386-8, 18083065, BIG 1-98 Collaborative and International Breast Cancer Study Groups.
45. Miller WR. ERBB2 status and outcome of endocrine treatment. Lancet Oncol 2008, 9:4-5. 10.1016/S1470-2045(07)70389-3, 18177812.
46. Lal P, Tan LK, Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol 2005, 123:541-546. 10.1309/YMJ3A83TB39MRUT9, 15743737.
47. Ma CX, Adjei AA, Salavaggione OE, Coronel J, Pelleymounter L, Wang L, Eckloff BW, Schaid D, Wieben ED, Adjei AA, Weinshilboum RM. Human aromatase: gene resequencing and functional genomics. Cancer Res 2005, 65:11071-11082. 10.1158/0008-5472.CAN-05-1218, 16322257.
48. Wang L, Ellsworth KA, Moon I, Pelleymounter LL, Eckloff BW, Martin YN, Fridley BL, Jenkins GD, Batzler A, Suman VJ, Ravi S, Dixon JM, Miller WR, Wieben ED, Buzdar A, Weinshilboum RM, Ingle JN. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to Neoadjuvant therapy with aromatase inhibitors. Cancer Res 2010, 70:319-328. 10.1158/0008-5472.CAN-09-3224, 2804935, 20048079.
49. Colomer R, Monzo M, Tusquets I, Rifa J, Baena JM, Barnadas A, Calvo L, Carabantes F, Crespo C, Muñoz M, Llombart A, Plazaola A, Artells R, Gilabert M, Lloveras B, Alba E. A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin Cancer Res 2008, 14:811-816. 10.1158/1078-0432.CCR-07-1923, 18245543.
50. Garcia-Casado Z, Guerrero-Zotano A, Llombart-Cussac A, Calatrava A, Fernandez-Serra A, Ruiz-Simon A, Gavila J, Climent MA, Almenar S, Cervera-Deval J, Campos J, Albaladejo CV, Llombart-Bosch A, Guillem V, Lopez-Guerrero JA. A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole. BMC Cancer 2010, 10:36. 10.1186/1471-2407-10-36, 2830181, 20144226.
51. Miller WR, Krause A, Larionov A, Evans DB, Anderson TJ, Dixon JM. Genes discriminating between breast cancers responsive or resistant to the aromatase inhibitor, letrozole. EJCMO 2010, 2:17-22.
52. Generali D, Buffa FM, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Papotti M, Dogliotti L, Bottini A, Harris AL, Fox SB. Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. J Clin Oncol 2009, 27:227-234. 10.1200/JCO.2007.13.7083, 19064988.
53. Akli S, Bui T, Wingate H, Biernacka A, Moulder S, Tucker SL, Hunt KK, Keyomarsi K. Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors. Clin Cancer Res 2010, 16:1179-1190. 10.1158/1078-0432.CCR-09-1787, 2822889, 20145171.
54. Miller WR, Larionov A, Anderson TJ, Evans DB, Dixon JM. Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole. Pharmacogenomics J 2010, [Epub ahead of print].
55. Mello-Grand M, Singh V, Ghimenti C, Scatolini M, Regolo L, Grosso E, Zambelli A, Da Prada GA, Villani L, Fregoni V, Baiardi P, Marsoni S, Miller WR, Costa A, Chiorino G. Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer. Breast Cancer Res Treat 2010, 121:399-411. 10.1007/s10549-010-0887-y, 20428938.
56. Hauglid Flågeng M, Haugan Moi L L, Dixon J M, Geisler J, Lien E A, Miller W R, Lønning P E, Mellgren G. Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. Br J Cancer 2009, 101:1253-1260. 10.1038/sj.bjc.6605324, 2768454, 19755984.
57. Miller WR, Larionov A, Renshaw L, Anderson TJ, Walker JR, Krause A, Sing T, Evans DB, Dixon JM. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. J Clin Oncol 2009, 27:1382-1387. 10.1200/JCO.2008.16.8849, 19224856.
58. Miller WR. Aromatase inhibitors: prediction of response and nature of resistance. Expert Opin Pharmacother 2010, 11:1873-1887. 10.1517/14656566.2010.487863, 20497094.
59. Miller WR, Dixon JM. Local endocrine effects of aromatase inhibitors within the breast. J Steroid Biochem Mol Biol 2001, 79:93-102. 10.1016/S0960-0760(01)00148-0, 11850212.
60. Geisler J, Lønning PE. Endocrine effects of aromatase inhibitors and inactivators in vivo: review of data and method limitations. J Steroid Biochem Mol Biol 2005, 95:75-81. 10.1016/j.jsbmb.2005.04.015, 15975785.
61. Ingle JN. Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer. Breast Cancer Res 2008, 10(Suppl 4):S1. 10.1186/bcr2161, 19241497.
62. Dowsett M, Pfi ster C, Johnston SR, Miles DW, Houston SJ, Verbeek JA, Gundacker H, Sioufi A, Smith IE. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clin Cancer Res 1999, 5:2338-2343.
63. ATAC Trialists Group Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: sub-protocol of the 'Arimidex TM and Tamoxifen alone or in combination' (ATAC) trial. Br J Cancer 2001, 85:317-324. 10.1054/bjoc.2001.1925, 2364083, 11487258, ATAC Trialists Group.
64. Miller WR. Biological rationale for endocrine therapy in breast cancer. Best Pract Res Clin Endocrinol Metab 2004, 18:1-32. 10.1016/S1521-690X(03)00044-7, 14687595.
65. Sourdaine P, Parker MG, Telford J, Miller WR. Analysis of the aromatase cytochrome P450 gene in human breast cancers. J Mol Endocrinol 1994, 13:331-337. 10.1677/jme.0.0130331, 7893351.
66. ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists Group Anastrozole alone or in combination with versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131-2139. ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists Group.
67. MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 1998, 50:151-196.
68. Makris A, Powles TJ, Allred DC, Ashley S, Ormerod MG, Titley JC, Dowsett M. Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response. Breast Cancer Res Treat 1998, 48:11-20. 10.1023/A:1005973529921, 9541185.
69. Miller WR, Dixon JM, Macfarlane L, Cameron D, Anderson TJ. Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. Eur J Cancer 2003, 39:462-468. 10.1016/S0959-8049(02)00600-7, 12751376.
70. Elledge RM, Osborne CK. Oestrogen receptors and breast cancer. BMJ 1997, 314:1843-1844. 10.1136/bmj.314.7098.1843, 2126973, 9224112.
71. Johnston SRD, Dowsett M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer 2003, 3:821-831. 10.1038/nrc1211, 14668813.
72. Fuqua SA, Cui Y. Estrogen and progesterone receptor isoforms: clinical significance in breast cancer. Breast Cancer Res Treat 2004, 87(Suppl 1):S3-10.
73. Mayordomo J, Llombart A, Martín M, Antón A, Barnadas A, Antolín S, Alés-Martínez J, Álvarez I. Randomized, multicenter, crossover phase II trial to compare exemestane (E) vs. anastrozole (A) in postmenopausal patients (pt) with advanced breast cancer (ABC) and positive hormone receptors (HR). Final efficacy analysis of GEICAM 2001-03 study. J Clin Oncol 2006, 24(Suppl):638.
74. Iaffaioli RV, Formato R, Tortoriello A, Del Prete S, Caraglia M, Pappagallo G, Pisano A, Gebbia V, Fanelli F, Ianniello G, Cigolari S, Pizza C, Marano O, Pezzella G, Pedicini T, Febbraro A, Incoronato P, Manzione L, Ferrari E, Marzano N, Quattrin S, Pisconti S, Nasti G, Giotta G, Colucci G, Southern Italy Oncology Group Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer. Br J Cancer 2005, 92:1621-1625. 10.1038/sj.bjc.6602579, 2362023, 15856035, Southern Italy Oncology Group.
75. Steele N, Zekri J, Coleman R, Leonard R, Dunn K, Bowman A, Manifold I, Kunkler I, Purohit O, Cameron D. Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure. Breast 2006, 15:430-436.
76. Chin YS, Beresford MJ, Ravichandran D, Makris A. Exemestane after non-steroidal aromatase inhibitors for post-menopausal women with advanced breast cancer. Breast 2007, 16:436-439. 10.1016/j.breast.2007.02.002, 17418575.
77. Carlini P, Michelotti A, Ferretti G, Ricci S, Giannarelli D, Pellegrini M, Cresti N, Di Cosimo S, Bria E, Papaldo P, Fabi A, Ruggeri EM, Milella M, Alimonti A, Salesi N, Cognetti F. Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients. Cancer Invest 2007, 25:102-105. 10.1080/07357900701224789, 17453821.
78. Gennatas C, Michalaki V, Carvounis E, Psychogios J, Poulakaki N, Katsiamis G, Voros D, Kouloulias V, Mouratidou D, Tsavaris N. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO). Tumori 2006, 92:13-17.